Treatment of Generalized Morphea with Oral 1.25-Dihydroxyvitamin D3

Caca‐Biljanovska, Nina; V'lckova-Laskoska, Marija; Dervendi, D. V.; Pesic, N. P.; Laskoski, Dimitri S.

doi:10.1007/978-1-4615-4857-7_44

Cited by 28 publications

(6 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Treatment options currently consist of topical, intralesional, or systemic corticosteroids, vitamin D analogs (calcitriol and calcipotriol), photochemotherapy, laser therapy, antimalarials, phenytoin, D-penicillamine, and colchicine, and they have met with variable success. [9][10][11][12] Immune modification of profibrotic cytokines would provide a novel means to treat morphea. Imiquimod (Aldara TM ) cream 5% is an immune response modifier that has demonstrated antiviral as well as antitumor activity both in vitro and in vivo.…”

Section: Discussionmentioning

confidence: 99%

Use of Imiquimod Cream 5% in the Treatment of Localized Morphea

Man

Dytoc

2004

J Cutan Med Surg

View full text Add to dashboard Cite

Fibrosis is characterized by the increased deposition of collagen and other matrix components by fibroblasts. This process occurs as a reaction to inflammation and is mediated by numerous cytokines including transforming growth factor beta (TGF-beta). Localized cutaneous scleroderma or morphea is characterized by fibrosis. Current treatment for morphea includes topical, intralesional, or systemic corticosteroids, vitamin D analog (calcitriol and calcipotriol), photochemotherapy, laser therapy, antimalarials, phenytoin, D-penicillamine, and colchicine, all with varying degrees of success. In this case report, imiquimod cream 5% (Aldara), which induces interferon and in turn inhibits TGF-beta, was employed to treat morphea.

show abstract

Section: Discussionmentioning

confidence: 99%

Use of Imiquimod Cream 5% in the Treatment of Localized Morphea

Man

Dytoc

2004

J Cutan Med Surg

View full text Add to dashboard Cite

show abstract

“…Topical vitamin D-vitamin D as topical calcipotriene 0.005% ointment-may inhibit effects on fibroblast proliferation, collagen synthesis, and T-cell activation. In some clinical studies, an improvement on this therapy was noted in limited numbers of patients [15,17].…”

Section: Treatmentmentioning

confidence: 99%

Systemic Sclerosis Mimics

Kodet¹,

Oreská²

2019

New Insights Into Systemic Sclerosis [Working Title]

View full text Add to dashboard Cite

Many clinical conditions are presenting with sclerosis of the skin and with tissue fibrosis. These conditions may be confused with systemic sclerosis (SSc, scleroderma). These diseases and disabilities are generally referred to as systemic sclerosis mimics or scleroderma-like syndromes. These disorders have very different etiologies and often an unclear pathogenetic mechanism. Distinct clinical characteristics, skin histology, and disease associations may allow distinguishing these conditions from systemic sclerosis and from each other. A histopathological examination with clinicopathological correlation for diagnosis is important to spare the patients from ineffective treatments and inadequate management. In this chapter, we discussed localized scleroderma, lichen sclerosus, nephrogenic systemic fibrosis, eosinophilic fasciitis, scleromyxedema, and scleredema. These are often detected in the primary care setting and referred to rheumatologists for further evaluation. Rheumatologists, or preferably in collaboration with a dermatologist, must be able to promptly recognize them to provide valuable prognostic information and appropriate treatment options for affected patients.

show abstract

“…Además, se ha observado que puede inhibir el crecimiento de los fibroblastos dérmicos humanos y regula su diferenciación. Por lo tanto, la efectividad terapéutica de este medicamento puede estar mediada por el efecto directo que ejerce sobre los fibroblastos y la síntesis de colágeno o al influir en la respuesta inmunitaria 42,59,60 .…”

Section: Sistémicounclassified

“…Este efecto permaneció durante un año después de haber suspendido el tratamiento. En este estudio se sugiere que este agente se puede utilizar en el tratamiento de la morfea generalizada 59 .…”

Section: Sistémicounclassified

Morfea o esclerodermia localizada

Gaviria¹,

Jiménez²,

Gutiérrez³

2014

rev. asoc. colomb. dermatol. cir. dematol.

View full text Add to dashboard Cite

La esclerodermia es un término que se deriva de las palabras griegas skleros (duro o endurecido) y dermis (piel). La esclerodermia localizada, también conocida con el nombre de morfea, es un trastorno fibrosante raro que afecta la piel y los tejidos adyacentes, y se limita casi de manera exclusiva a los tejidos derivados del mesodermo. La patogénesis no está dilucidada por completo, pero se sabe que es una enfermedad autoinmunitaria en la cual existen múltiples factores que contribuyen a aumentar las citocinas proinflamatorias, lo cual conduce a un desequilibrio entre la producción y la destrucción del colágeno, que finalmente va a favorecer la fibrosis que caracteriza a esta enfermedad. Aunque la morfea es un trastorno localizado de la piel, los pacientes con esta enfermedad comúnmente pueden tener síntomas sistémicos, como malestar general, fatiga, artralgias y mialgias, así como autoanticuerpos circulantes positivos. Se diferencia principalmente de la esclerosis difusa (esclerosis sistémica) por la ausencia de esclerodactilia, fenómeno de Raynaud, cambios capilares del lecho ungular y compromiso de órganos internos.

show abstract

Treatment of Generalized Morphea with Oral 1.25-Dihydroxyvitamin D3

Cited by 28 publications

References 9 publications

Use of Imiquimod Cream 5% in the Treatment of Localized Morphea

Use of Imiquimod Cream 5% in the Treatment of Localized Morphea

Systemic Sclerosis Mimics

Morfea o esclerodermia localizada

Contact Info

Product

Resources

About